Skip to content

L · 0HTC.L · BIOTECHNOLOGY

Cara Therapeutics, Inc. (0HTC.L) intrinsic value and stock valuation

$15.99as of 2026-11-21 · Mkt cap 24.33M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Cara Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values 0HTC.L with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from 0HTC.L’s statements →

Cara Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Stamford, CT 06902 caratherapeutics.com

How the business is doing

Fiscal 2012–2024, USD

Revenue
$7.14M-18.5% 5y CAGRd
20122024
Net income
-$-70.87M
20122024
Free cash flow
-$-61.96M
20122024
Total equity
-$-4.59M
20122024

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2012–2024, USD
20242023202220212020
Revenue$7.14M$21M$41.9M$23M$135.1M
Operating income-$-55.78M-$-121.5M-$-87.53M-$-89.08M$5.38M
Net income-$-70.87M-$-118.51M-$-85.47M-$-88.44M$8.41M
EPSd-$-46.63M-$-2.19M-$-1.59M-$-1.74M$175.5K
Operating cash flow-$-60.92M-$-92.08M-$-78.73M-$-60.09M-$-5.49M
Capital expenditure-$-1.05M-$-2.38M-$-40K-$-40K-$-350K
Free cash flow-$-61.96M-$-94.45M-$-78.77M-$-60.13M-$-5.84M
Total assets$43.8M$125.8M$182.2M$247.1M$271.2M
Total debt$44.5M$43.2M$1.92M$3.67M$5.28M
Net debt$6.54M-$-8.61M-$-62.23M-$-9.78M-$-26.41M
Total equity-$-4.59M$57.1M$158.8M$227.5M$249M
Cash and short-term investments$37.9M$100.8M$145.8M$167M$180.9M
Income statement
20242023202220212020
Revenue$7.14M$21M$41.9M$23M$135.1M
Cost of revenue$810K$113.6M$7.51M$1.55M$107.1M
Gross profit$6.33M-$-92.58M$34.4M$21.5M$28M
Research and development expenses$32.8M$108.4M$91.8M$82.6M$107.7M
Selling, general and administrative expenses$26.4M$28.9M$31.4M$30.6M$22.6M
Other expenses$2.96M-$-108.38M-$-1.26M-$-2.57M-$-107.74M
Operating expenses$62.1M$28.9M$121.9M$110.6M$22.6M
Cost and expenses$62.9M$142.5M$129.4M$112.1M$129.7M
Interest income$2.83M$3.59M$2.06M$600K$2.06M
Interest expense$8.47M$600K$0.00$0.00$0.00
Depreciation and amortization$190K$260K$1.67M$1.55M$1.01M
Ebitda-$-62.6M-$-121.24M-$-83.8M-$-86.89M$6.4M
Operating income-$-55.78M-$-121.5M-$-87.53M-$-89.08M$5.38M
Total other income/expenses, net-$-15.48M$2.98M$2.06M$640K$2.33M
Income before tax-$-71.27M-$-118.51M-$-85.47M-$-88.44M$7.72M
Income tax expense-$-400K$0.00$0.00$0.00-$-690K
Net income-$-70.87M-$-118.51M-$-85.47M-$-88.44M$8.41M
Weighted average shares outstanding$1.52M$54.1M$53.7M$50.7M$47.4M
Weighted average diluted shares outstanding$1.52M$54.2M$53.7M$50.7M$47.9M
Balance sheet
20242023202220212020
Cash and short-term investments$37.9M$100.8M$145.8M$167M$180.9M
Net receivables$4.5M$2.77M$4.45M$1.15M$2.06M
Inventory$900K$2.82M$2.38M$2.58M$0.00
Total current assets$43.8M$116.2M$168.9M$173.3M$195.1M
Property, plant and equipment, net$0.00$8.19M$1.98M$3.6M$5.12M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$1.5M$11.4M$70.2M$71M
Total non-current assets$0.00$9.69M$13.3M$73.8M$76.1M
Total assets$43.8M$125.8M$182.2M$247.1M$271.2M
Accounts payable$1.43M$11.6M$9.6M$5.62M$4.89M
Short-term debt$0.00$0.00$3.84M$3.51M$3.2M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$3.97M$25.6M$23.5M$17.6M$18.5M
Long-term debt$44.5M$43.2M$0.00$1.92M$3.67M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$44.5M$43.2M$0.00$1.92M$3.67M
Capital lease obligations$0.00$6.09M$1.92M$3.67M$5.28M
Total liabilities$48.4M$68.8M$23.5M$19.5M$22.2M
Common stock$10K$50K$50K$50K$50K
Retained earnings-$-755.61M-$-684.75M-$-566.23M-$-480.76M-$-392.32M
Accumulated other comprehensive income (loss)$0.00-$-260K-$-1.67M-$-360K$70K
Total equity-$-4.59M$57.1M$158.8M$227.5M$249M
Total investments$0.00$50.5M$93M$223.7M$220.2M
Total debt$44.5M$43.2M$1.92M$3.67M$5.28M
Net debt$6.54M-$-8.61M-$-62.23M-$-9.78M-$-26.41M
Cash flow statement
20242023202220212020
Net income-$-70.87M-$-118.51M-$-85.47M-$-88.44M$8.41M
Depreciation and amortization$190K$260K$1.67M$1.55M$1.01M
Stock-based compensation$0.00$13.7M$17.7M$20.8M$14.8M
Change in working capital-$-15.1M$6.89M-$-12.92M$5.26M-$-7.37M
Accounts receivable$2.02M$490K-$-3.3M$910K-$-280K
Inventory-$-1.04M-$-440K$200K-$-2.58M$0.00
Accounts payable-$-21.44M$3.27M$5.68M-$-1.02M-$-2.78M
Net cash provided by operating activities-$-60.92M-$-92.08M-$-78.73M-$-60.09M-$-5.49M
Investments in property, plant and equipment-$-1.05M-$-2.38M-$-40K-$-40K-$-350K
Acquisitions, net$0.00-$-45.84M-$-128.75M$70K$19.9M
Net cash used for investing activities$48.7M$43.5M$128.7M-$-4.75M-$-20.27M
Common stock issued$0.00$1.68M$310K$46.6M$39.1M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-3.6M$38.2M$310K$46.6M$39.1M
Net change in cash-$-14.28M-$-10.47M$50.7M-$-18.23M$13.4M
Cash at end of period$37.9M$53.7M$64.2M$13.5M$31.7M
Operating cash flow-$-60.92M-$-92.08M-$-78.73M-$-60.09M-$-5.49M
Capital expenditure-$-1.05M-$-2.38M-$-40K-$-40K-$-350K
Free cash flow-$-61.96M-$-94.45M-$-78.77M-$-60.13M-$-5.84M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Cara Therapeutics, Inc.

        Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

        CEO
        Christopher A. Posner
        Employees
        10
        Beta
        0.41

        Explore

        Frequently asked questions

        What is the intrinsic value of Cara Therapeutics, Inc. (0HTC.L)?

        InvestorsCraft does not currently publish an intrinsic value for 0HTC.L. How the IC value is calculated.

        Is 0HTC.L undervalued?

        InvestorsCraft does not publish an undervaluation signal for 0HTC.L at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.